---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-204161"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:09:15.337101+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Perspective Therapeutics updates VMT-α-NET Ph1/2a data and preliminary cash position

## Summary
- Preliminary cash & short-term investments as of Mar 31, 2026 disclosed; unaudited, subject to final adjustments.
- VMT-α-NET Phase 1/2a data show durable disease control across all doses; responses deepen over time.
- Company says profile supports potential registration study at current dose level.
- Manufacturing update: daily production at regional sites for ready-to-administer 212Pb products.
- Expanding pipeline includes CCK2R81 targeting and other solid tumor programs.

## SEC filing metadata
- accession: 0001193125-26-204161
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526204161/0001193125-26-204161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526204161/catx-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-204161
- JSON: https://secwatch.observer/filing/0001193125-26-204161.json
- Plain text: https://secwatch.observer/filing/0001193125-26-204161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.